TrialBMC medicine2023

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.

Jin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.